OpiCalc Logo

OpiCalc

989 Clinical Tools

Logo
OpiCalc
APGAR ScoreAssisted Delivery (FIGO)BPP (Manning Score)Bishop ScoreCARPREG II Cardiac RiskCervical Cancer StagingContraceptive Pearl IndexDoppler Matrix (UA/MCA)EFW (Hadlock)Endometrial StagingEndometrial ThicknessFGR Criteria (Consensus)FSFI (Sexual Function)Ferriman-Gallwey ScoreFetal Anemia (MCA PSV)GDM Diagnostic CriteriaGPA History IndicatorGail Model Breast RiskGestational Dating (LMP)HIV PMTCT ProtocolIOTA Simple RulesIVF Due Date & AMHIron Deficit (Ganzoni)Labour Progress (WHO)Maternal Sepsis (qSOFA)O-RADS ClassificationOvarian Cancer StagingPAS Hemorrhage RiskPPH Protocol (FIGO)Preeclampsia (ACOG)Rho(D) Dose (K-B)Rotterdam PCOS CriteriaSyphilis ManagementTORCH FrameworkVBAC Success ProbabilityVulvar Cancer StagingWeight Gain (IOM)mWHO Cardiac Risk
OpiCalc Logo

OpiCalc

Open-access clinical infrastructure. Built to the standard every clinician deserves — fast, private, and free.

Zero data stored
Always free
Our mission & transparency

Get in Touch

Tool request, clinical feedback, or partnership inquiry — we read everything.

WhatsApp feedback
Email us
Partnership inquiry

© 2026 OpiCalc • Calculated Care

ProtocolsAboutPrivacyTerms

Endometrial Staging

Endometrial Staging (2023)

Molecular & Pathology Integrated

I

Confined to Corpus

IA (≤50% Myometrium) | IB (>50% Myometrium) | IC (Integrated Molecular Stage)

II

Cervical Stroma Involved

Does NOT extend beyond uterus

III

Local / Regional Spread

IIIA (Serosa/Adnexa) | IIIB (Vagina/Parametrium) | IIIC (Lymph Nodes)

IV

Bladder / Rectum / Distant

IVA (Bowel/Bladder Mucosa) | IVB (Distant Metastasis)

Molecular update: Stage I includes POLE mutations (favorable) and p53 mutations (unfavorable).

Guidelines & Evidence

Clinical Details

Section 1

When to Use

Primary Clinical Uses

Surgical and pathological staging of endometrial carcinoma and carcinosarcoma
Directing postoperative adjuvant treatment (radiation vs chemotherapy)

The 2023 Molecular Revolution

The 2023 update was the most radical change in history. It officially incorporated molecular classification (POLEmut, MMRd, NSMP, p53abn) into the staging system. A p53-abnormal tumor is now heavily upstaged regardless of myometrial invasion, whereas a POLE-mutated tumor may be downstaged due to exceptional prognosis.
Section 2

Formula & Logic

Stage I — Confined to Uterus (Ovary involvement nuanced)

IA1Non-aggressive histology, confined to endometrium/polyp
IA2Non-aggressive histology, <50% myometrial invasion
IA3Low-grade endometrioid tracking to ovaries (new criteria)
IBNon-aggressive histology, ≥50% myometrial invasion
ICAggressive histology (e.g., serous, clear cell), ANY myometrial invasion

Stage II — Cervical Stroma or Extrauterine extensions

IIAInvasion of cervical stroma
IIBSubstantial lymphovascular space invasion (LVSI)
IICAggressive histology with cervical stromal invasion

Stage III — Local/Regional Spread

IIIAInvasion of serosa, adnexa (non-Grade 1 endometrioid)
IIIBVaginal or parametrial involvement
IIIC1Pelvic lymph node involvement (micro or macro)
IIIC2Para-aortic lymph node involvement

Stage IV — Distant Spread

IVAInvasion of bladder/bowel mucosa
IVBDistant metastasis, including intra-abdominal or inguinal nodes
Section 3

Pearls/Pitfalls

Molecular Modifiers (The "m" suffix)

Prognosis classification: POLEmut (favorable), MMRd (intermediate), p53abn (poor).
If molecular profiling is done, append "m" to the stage (e.g., IAm).
Any p53abn tumor with any myometrial invasion is automatically staged as IICm (high risk), overriding its anatomical Stage I boundaries.
A stage II (cervical stroma) tumor with POLE mutation is distinctly down-staged biologically due to nearly zero recurrence risk.
Section 4

Next Steps

Clinical Action

01
Determine initial anatomical stage from TAH-BSO pathology.
02
Perform IHC testing for MMR proteins and p53, plus POLE sequencing if available.
03
Apply upstaging/downstaging rules based on 2023 FIGO molecular integration.
04
Route patient into PORTEC-guided therapeutic pathways (e.g., observation vs vaginal brachytherapy vs pelvic EBRT vs systemic chemo).
Section 5

Evidence Appraisal

2023 Landmark Release

FIGO staging of endometrial cancer: 2023.

Berek JS et al. • Int J Gynaecol Obstet.. 2023;The defining document fundamentally restructuring staging to align structural pathology with genomic reality.

Section 6

Literature

TCGA Influence

The 2023 system was heavily catalyzed by The Cancer Genome Atlas (TCGA) Research Network, which in 2013 entirely redefined endometrial cancer biology by proving that distinct molecular subgroups exist and wildly outpredict traditional anatomical grade and stage.

Last Comprehensive Review: 2026

Related Obstetrics Tools

APGAR Score
Assisted Delivery
Bishop Score
BPP
CARPREG II Cardiac Risk
Cervical Cancer Staging
Contraceptive Pearl Index
Doppler Matrix
EFW
Endometrial Staging
Have feedback about this calculator?Let us know.